Acute lymphoblastic leukemia in adults

Current Treatment Options in Oncology

Volumn 1, Issue 1, 2000, Pages 19-29

  Litzow, Mark R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Acute Lymphoblastic Leukemia; Daunorubicin; Flavopiridol; Main Drug Interaction; Main Side Effect

Indexed keywords

ANTINEOPLASTIC AGENT; LEUKOCYTE ANTIGEN; TUMOR ANTIGEN;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; CLINICAL TRIAL; DIET; DISEASE FREE SURVIVAL; HUMAN; IMMUNOLOGY; KARYOTYPING; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; REVIEW; RISK FACTOR; SKULL IRRADIATION;

ADULT; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DIET; DISEASE-FREE SURVIVAL; HUMANS; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, ACUTE; PROGNOSIS; RISK FACTORS;

EID: 0034174807     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-000-0012-2     Document Type: Article

References (20)

1. Pui C-H: Childhood leukemias. N Engl J Med 1995, 332:1618–1630.
2. Stock W: Treatment of adult lymphoblastic leukemia: risk-adapted strategies. Hematology 1999: 87–96. An excellent and succinct current review of the therapy of adult ALL.
3. Larson RA, Dodge RK, Burns CP, et al.: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811. Blood 1995, 85:2025–2037. A large trial demonstrating the effectiveness of multi-agent chemotherapy optimally applied in the cooperative group setting. Outlines outcome of therapy related to established risk factors.
4. Wetzler M, Dodge RK, Mrozek K, et al.: Prospective karyotype analysis in acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood 1999, 93:3983–3993.
5. Hoelzer D, Ludwig W-D, Thiel E, et al.: Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996, 87:495–508.
6. Forman SJ: Transplant approaches to high-risk ALL. Hematology 1999:96–101.
7. Zhang M-J, Hoelzer D, Horowitz MM, et al.: Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. Ann Intern Med 1995, 123:428–431.
8. Sebban C, Lepage E, Vernant J-P, et al.: Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. J Clin Oncol 1994, 12:2580–2587.
9. Hoelzer D, Thiel E, Löffler H, et al.: Intensified chemotherapy and mediastinal irradiation in adult T-cell acute lymphoblastic leukemia. In Acute Lymphoblastic Leukemia. Edited by Gale RP, Hoelzer D. New York, NY: Liss; 1990:221–229.
10. Kersey JH, Weisdorf D, Nesbit ME, et al.: Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. N Engl J Med 1987, 317:461–467.
11. Attal M, Blaise D, Marit G, et al.: Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1995, 86:1619–1628.
12. Weisdorf DJ, Billett AL, Hannan P, et al.: Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood 1997, 90:2962–2968. Retrospectively addresses the difficult question of whether to consider autologous or unrelated donor allogeneic transplant for patients lacking an HLA-matched sibling donor.
13. Kurtzberg J, Keating M, Moore JO, et al.: 2-amino-9-B-D-Arabinosyl-6-methoxy-9H-Guanine (GW506U; Compound 506U) is highly active in patients with T-cell malignancies: results of a phase I trial in pediatric and adult patients with refractory hematologic malignancies. Blood 1996, 88:669a.
14. Byrd JC, Waselenko JK, Shinn CA, et al.: FR90128, a novel antitumor bicyclic depsipeptide has marked in vitro activity against both the K-562 cell line and human acute leukemia cells. Blood 1997, 90:238a.
15. Shinn CA, Byrd JC, Waselenko JK, et al.: UCN-01 has significant in vitro activity in both the resistant K-562 cell line and human acute leukemia cells. Blood 1997, 90:246a.
16. Waselenko JK, Byrd JC, Shinn CA, et al.: Flavopiridol has marked in vitro activity against both the K-562 cell line and human acute leukemia cells. Blood 1997, 90:248a.
17. Akao Y, Mizoguchi H, Kojima S, et al.: Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein. Br J Haematol 1998, 102:1055–1060.
18. Kolitz JE, O’Mara V, Willemze R, et al.: Treatment of acute lymphoblastic leukemia with campath-1H: initial observations. Blood 1994, 84:301a.
19. Messinger Y, Chen C-L, O’Neill K, et al.: Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Blood 1999, 94(suppl 1):295a.
20. Druker BJ, Kantarjian H, Sawyers CL, et al.: Activity of an ABL specific tyrosine kinase inhibitor in patients with bcr-abl positive acute leukemias, including chronic myelogenous leukemia in blast crisis. Blood 1999 94 (suppl 1):697a.